assays react with circulating molecular form(s) of PTH other than PTH(1-84) (1) (2) (3) . These molecular form(s) are not recognized by antibodies specific for the sequence 1-12 of the 84-amino acid structure of PTH (4, 5 ) . This does not impair immunoreactivity with the reporter antibody in commercial I-PTH assays because most N-terminal antibodies react with an epitope distal to position 14 (6 ) . In healthy individuals, these non-(1-84) molecular form(s) account for up to 20% of circulating I-PTH immunoreactivity (1 ) and behave as C-terminal fragment(s), increasing the non-(1-84) relative proportion with hypercalcemia and decreasing it with hypocalcemia (1, 7, 8 ) . In hemodialyzed patients, the non-(1-84) form(s) may account for up to 55% of I-PTH immunoreactivity (2 ) . This increased proportion in renal failure patients is probably best explained by decreased renal clearance of I-PTH molecular form(s) behaving like a C-terminal fragment (1, 2, 9, 10 ) . This accumulation of non-(1-84) PTH in renal failure is pertinent to the increased nonsuppressible frac-tion of I-PTH found in that condition (2, 3, (11) (12) (13) (14) (15) (16) and also to the fact that I-PTH values overestimated parathyroidmediated osseous abnormalities in uremia (17 ) . It is unclear whether non-(1-84) PTH could be important in explaining increases in I-PTH in early renal failure and as the condition progresses. This study was thus planned to study the relationship between glomerular filtration rate (GFR) and non-(1-84) PTH in the genesis and evolution of increasing I-PTH in renal failure.
Subjects and Methods
Thirty-one patients with progressive renal failure participated in the study. Twenty-six healthy subjects who had participated in parathyroid function and I-PTH HPLC composition studies (1, 8 ) served as controls. Twelve hemodialyzed patients who also participated in similar studies (2 ) were used as examples of end-stage renal failure.
experimental protocol
The protocol was approved by a local ethics committee. All participants signed an informed consent form. All subjects were studied while maintaining their usual diet. Hemodialyzed patients were studied in October, at the end of summer, and progressive renal failure patients were studied in May, at the end of winter. Blood was obtained from all subjects after an overnight fast where water was permitted. A 24-h urine specimen was also obtained from patients with progressive renal failure. Ionized calcium (Ca 2ϩ ), phosphate, alkaline phosphatase, creatinine, I-PTH and C-terminal PTH (C-PTH), 25- (20, 21 ) when sera obtained under various calcium concentrations were fractionated by HPLC. In the company's brochure, the stated detection limit of the assay is 0.1 pmol/L. The intraassay CV for duplicates was 3.1%. Serum C-PTH was measured by an in-house C-PTH assay described previously (7, 8 ) . This assay detects predominantly large C-terminal fragments of the hormone, PTH(1-84), being four-to sixfold less reactive on a molar basis than PTH(39-84). The antigenic determinant in this assay is in the region (65-84) of the PTH molecule; therefore, PTH(1-34), PTH(39-68), and PTH(44-68) are nonreactive. The detection limit was 1 pmol/L using 3 SD from the zero calibrator run in quadruplicate in 10 different assays. The intraassay CV at 50% binding was 3.3%. For I-and C-PTH measurements, all patients with progressive renal failure were measured in the same assay.
To analyze individual molecular forms of PTH detected by both assays, one pool was prepared from equal volumes of serum from each of the individuals in each of the three subgroups of patients with progressive renal failure, and fractionated once by HPLC. Results from the healthy subjects and patients with end-stage renal failure have been presented previously (1, 2, 8 ) . Serum PTH was first extracted on Sep-Pack Plus C 18 cartridges (Waters Chromatography Division) (22 ) . Samples were eluted with 3 mL of 800 mL/L acetonitrile in 1 g/L trifluoroacetic acid. After evaporation with nitrogen, the residual volume was freeze-dried and reconstituted in 2 mL of 1 g/L trifluoroacetic acid for HPLC analysis. Each sample was then loaded on a C 18 Bondapak analytical column (3.9 ϫ 300 mm; Waters), and eluted with a noncontinuous 15-50% linear gradient of acetonitrile in 1 g/L trifluoroacetic acid, delivered at 1.5 mL/min for 65 min by a Bio-Rad Model 2700 HPLC (Bio-Rad). The 1.5-mL fractions were collected in polypropylene tubes precoated with 1 g/L bovine serum albumin in water. After evaporation with nitrogen, each fraction was freeze-dried and reconstituted to 1 mL with 7 g/L bovine serum albumin in water, and appropriate volumes were assayed for I-PTH. Recovery during all these procedures was Ͼ85%. Furthermore, PTH(1-84) and PTH(7-84) calibrators, added to hypoparathyroid serum and processed as described, eluted as single peaks at the expected positions, showing that PTH was not degraded during the above procedures.
mathematical and statistical analysis
Results are presented as means Ϯ SD. Comparisons between groups were performed by a one-way ANOVA and the Student-Newman-Keuls comparison test for 2 by 2 comparisons. Standard methods were used for simple and multivariate regression analysis. HPLC profiles were corrected to 100% recovery, and the surface under each peak was evaluated by planimetry using the peak-fitting module of Origin 3.5 (Microcal Software).
Results
The characteristics of the groups studied are summarized in Table 1 . To better outline differences in relation to GFR, patients with progressive renal failure were subdivided into three groups: GFR between 60 and 100 mL ⅐ min Ϫ1 ⅐ Fig. 1) , a positive correlation was found between the GFR and Ca 2ϩ or 1,25(OH) 2 D value, whereas a negative correlation was found between GFR and phosphate, I-PTH, or C-PTH. When only patients with GFR Ͼ30 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 were considered (n ϭ 23), only the negative correlation between the GFR and I-PTH (r ϭ Ϫ0.469; P ϭ 0.024) or C-PTH (r ϭ Ϫ0.578; P ϭ 0.004) values remained significant. The HPLC profiles of I-PTH in healthy individuals, the three groups of patients with GFRs from 100 to Ͻ30 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 , and in hemodialyzed patients are illustrated in Fig. 3 . The results are expressed as a percentage of total immunoreactivity to outline differences more clearly. Two peaks are identified with the two PTH assays, one comigrating with PTH(1-84) at 53 min, and another one at 49 -51 min in front of PTH(1-84). This latter peak represents 21% of I-PTH immunoreactivity in healthy individuals, 32% in patients with a GFR Ͻ30 mL ⅐ min Ϫ1 ⅐ 1.73 m
Ϫ2
, and 50% in hemodialyzed patients. The percentage of non-(1-84) PTH correlated with serum creatinine (r 2 ϭ 0.99; P Ͻ0.0001) even when the group of hemodialyzed patients was excluded (r 2 ϭ0.94; P ϭ 0.007). With each decrease in GFR (or increase in serum creatinine), non-(1-84) PTH represented a greater proportion of the I-PTH immunoreactivity measured. For a 5-fold increase in PTH(1-84) between healthy subjects and hemodialyzed patients, non-(1-84) PTH increased 18-fold, i.e., a 3.6-fold difference.
Discussion
This study was designed to evaluate the role of non-(1-84) PTH, detected by commercial intact PTH assays (3 ), in the evaluation of the increased I-PTH observed in progressive renal failure. Increased I-PTH concentrations have been shown to be closely associated with the osseous abnormalities of secondary hyperparathyroidism in end-stage renal failure (17, (23) (24) (25) (26) . We demonstrated previously that non-(1-84) PTH behaves as a C-terminal fragment (1 ) and accumulates in hemodialyzed patients to account for 50% of I-PTH immunoreactivity compared with 20% in healthy individuals (2 ) . We studied five groups of individuals with GFR values ranging from normal to almost nonexistent. This enabled us to study I-PTH composition as a function of the GFR. I-and C-PTH were increased in patients with a GFR between 30 and 100 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 even if mean Ca were excluded. Our study was performed at the end of winter, and this may explain why 35% of our patients with progressive renal failure had 25(OH)D concentrations below the lower limit of normal and why 25(OH)D was associated with I-PTH concentrations. It remains that the biochemical findings in our patients were similar to those described by others in similar patients (27) (28) (29) (30) (31) , with minor differences from one study to the other. In particular, the concentration of I-PTH relative to the GFR of the patients is surprisingly similar (28 -30 ) when the same or similar I-PTH assays are used.
The composition of I-PTH as a function of the GFR was our main focus. There were minor changes in composition before a GFR Ͻ30 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 was reached. At this stage, PTH(1-84) had decreased from 79% in healthy individuals to 68% in patients with progressive renal failure, and non-(1-84) had increased from 21% in healthy individuals to 32% in patients with progressive renal failure. The greatest changes were seen in hemodialyzed patients, where PTH(1-84) and non-(1-84) PTH each accounted for one-half of the I-PTH. This means that the accumulation of non-(1-84) PTH becomes a more significant phenomenon in the last stage of progressive renal failure evolution. For an 8-fold increase in total I-PTH between healthy individuals and hemodialyzed patients, there is a 5-fold increase in PTH(1-84) but an 18-fold increase in non-(1-84) PTH. This 3.6-fold difference between PTH(1-84) and non-(1-84) PTH may well represent decreased renal clearance of this C-terminal fragment. It is interesting to note that the difference in C-PTH between healthy individuals and hemodialyzed patients is also 18-fold; this assay reacts predominantly with C-terminal fragments, reinforcing the decreased clearance hypothesis. Overall, our study demonstrated that the GFR influences the composition of I-PTH in progressive renal failure, with non-(1-84) PTH representing a greater proportion of total I-PTH immunoreactivity with each decrease. When renal function is abolished, I-PTH concentrations 1.6-fold higher are required to achieve PTH(1-84) concentration similar to those in healthy subjects. The role of non-(1-84) PTH in the PTH resistance of renal failure remains to be elucidated because theoretically, this large C-terminal fragment could bind to both the classical PTH/PTHrP (32-34 ) and C-PTH (35 ) receptors and therefore interfere with PTH(1-84) biological effects. Recent results obtained in vivo in rats suggest that the synthetic fragment PTH(7-84), possibly related to non-(1-84) PTH, is a potent in vivo antagonist of PTH(1-84) (36 ) . The recent introduction of a "whole" PTH assay free of interference from non-(1-84) PTH should be very helpful in clarifying these issues (37, 38 ) .
